PureTech Health est suivi par de nombreux journalistes et investisseurs dans le monde. Nous rassemblons ici les dernières actualités concernant PureTech Health.

19 février·
Benzinga
PureTech Health Announces That The FDA And European Commission Have Granted Orphan Drug Designation To Deupirfenidone For The Treatment Of Idiopathic Pulmonary Fibrosis
3 janvier·
Yahoo
PureTech Health plc (LON:PRTC) is favoured by institutional owners who hold 73% of the company
18 décembre·
Yahoo
PureTech Appoints Robert Lyne as Chief Executive Officer
18 décembre·
Benzinga
PureTech Names Interim CEO Robert Lyne As Chief Executive Officer
8 décembre·
Yahoo
PureTech Health Completes End-of-Phase 2 Meeting With FDA for Deupirfenidone to Treat Idiopathic Pulmonary Fibrosis
8 décembre·
Benzinga
Meihua International Medical Technologies, Fly-E Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
8 décembre·
Benzinga
PureTech Confirms Phase 3 SURPASS-IPF For Deupirfenidone (LYT-100) On Track For H1 2026 After FDA End-Of-Phase 2 Meeting
5 décembre·
Benzinga
PureTech Health Announces Initial Topline Results From Phase 1b Clinical Trial Evaluating LYT-200, Anti-Galectin-9 Monoclonal Antibody, In Patients With r/r AML And High-Risk MDS
29 septembre·
Benzinga
PureTech Presents Phase 2b Open-Label Extension Data Showing Deupirfenidone Stabilizes Lung Function In IPF With Favorable Tolerability
11 septembre·
Yahoo
PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers
28 août·
Benzinga
PureTech Health H1 EPS $(0.19) Down From $(0.15) YoY, Sales $1.85M Up From $288.00K YoY
21 août·
Yahoo
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
21 août·
Benzinga
PureTech Health Showcases Phase 2b Data At IPF Summit, Launches Celea Therapeutics To Advance Deupirfenidone Toward Phase 3
12 août·
Yahoo
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
12 août·
Benzinga
Puretech Health Launches Celea Therapeutics To Transform Treatment Of Respiratory Diseases
16 juillet·
Yahoo
PureTech Announces Leadership Transition
16 juillet·
Benzinga
PureTech CEO Bharatt Chowrira Steps Down After Eight Years; Board Appoints Robert Lyne As Interim Chief Executive Officer
26 juin·
Yahoo
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
16 juin·
Yahoo
PureTech Health: Results of Annual General Meeting
22 mai·
Yahoo
PureTech to Present at the Jefferies Global Healthcare Conference

Communiqués de presse relatifs à l'action PureTech Health

PureTech Health publie régulièrement sur son site web des communiqués pertinents pour les investisseurs.

18 novembre•
PureTech Health
Puretech Health Says Gelesis Receives $30M Plenity Order From Ro
10 septembre•
PureTech Health
PureTech Says Vor Biopharma Announces Vor33 Granted U.S. FDA Fast Track Designation For Acute Myeloid Leukemia
22 juillet•
PureTech Health
PureTech Health Says Akili Interactive Introduced New Features To EndeavorRx Treatment
19 juillet•
PureTech Health
PureTech Health Says Gelesis To Become Publicly Traded Co Via Merger With Capstar SPAC
9 juillet•
PureTech Health
Puretech Founded Entity Vor Biopharma Announces Collaboration With Janssen To Develop Engineered Hematopoietic Stem Cell Transplants Combined With A Bi-Specific Antibody Therapy For Acute Myeloi
7 juillet•
PureTech Health
PureTech Announces Clinical Trial And Supply Agreement With BeiGene
16 juin•
PureTech Health
Puretech Acquires Remaining Interest In Founded Entity Alivio Therapeutics
15 avril•
PureTech Health
Puretech Health FY Operating Loss Of $119.5 Mln
18 mars•
PureTech Health
Puretech Health Says Stephen Muniz To Retire As Chief Operating Officer
2 mars•
PureTech Health
Puretech Health Notes Karuna Pricing $250 Mln Public Offering
8 février•
PureTech Health
PureTech Health Says Vedanta Biosciences Appointed Mark Mullikin As CFO
5 février•
PureTech Health
PureTech Founded Entity Vor Biopharma Announces Pricing Of Initial Public Offering
18 janvier•
PureTech Health
PureTech Health Syas Vor Files IPO Registration Statement On Nasdaq
5 janvier•
PureTech Health
PureTech Health Appoints George Farmer As CFO
11 décembre•
PureTech Health
Puretech Health Starts LYT-200 Clinical Trial In Solid Tumors
10 décembre•
PureTech Health
PureTech Initiates Phase 2a trial of LYT-100 in Lymphedema
13 novembre•
PureTech Health
Puretech Health Says Guidance For Exchanging Ordinary Shares Into ADSS
13 novembre•
PureTech Health
Puretech Health Start Nasdaq Trading On Nov. 16
30 septembre•
PureTech Health
Puretech Health Says Vedanta Biosciences Awarded By BARDA Up to $76.9 Mln to Advance VE303
25 août•
PureTech Health
Puretech Health Says Sonde Makes Acquisition In Vocal Biomarker Space
23 juin•
PureTech Health
Puretech Health Says Akili Received European Approval to Market EndeavorRx
26 mai•
PureTech Health
Puretech Health Sells 555,500 Shares Of Karuna Therapeutics For About $45 Mln
3 mars•
PureTech Health
Puretech Health Says Clinical Trial Initiated Of Wholly-Owned Candidate
15 janvier•
PureTech Health
Puretech Health Says Akili's New ADHD Trial Met Primary Endpoint

PureTech Health News 2026

Cette page contient toutes les actualités actuelles, analyses et communiqués de presse pour l'action PureTech Health (PRTC.L, ISIN : GB00BY2Z0H74). Cela inclut les actualités Eulerpool, les analyses d'entreprise et les communiqués de presse officiels. Les données sont mises à jour régulièrement pour fournir aux investisseurs un aperçu complet des derniers développements chez PureTech Health.

PureTech Health Action

PureTech Health PureTech Health est une entreprise innovante spécialisée dans le développement de thérapies médicales et de solutions novatrices. La société a été fondée en 2002 par Daphne Zohar et a son siège à Boston, aux États-Unis. PureTech Health est cotée à la Bourse de Londres et est devenue l'une des principales sociétés de biotechnologie ces dernières années.